Andere talen Pulmonx Corporation

Aandelen

LUNG

US7458481014

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,3 ^USD	-2,93%		-2,67%	-42,75%

26/02	Pulmonx Corporation kondigt de behandeling aan van de eerste patiënt met het Aeriseal System in Convert II Pivotal Trial	CI
23/02	Pulmonx-aandelen dalen na Wells Fargo Downgrade	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024	10/04
Pulmonx Appoints Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer	02/04
Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024	02/04
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/03
Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial	27/02
Pulmonx meldet Behandlung des ersten Patienten mit dem AeriSeal®-System in der CONVERT-II-Zulassungsstudie	27/02
Pulmonx annonce le traitement du premier patient par système AeriSeal® dans l'essai pivot CONVERT II	27/02
Pulmonx annuncia il trattamento del primo paziente con il sistema AeriSeal® nello studio pivotale CONVERT II	27/02
Pulmonx anuncia el tratamiento del primer paciente con el sistema AeriSeal® en el ensayo pivotal CONVERT II	27/02
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial	26/02
Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial	26/02
North American Morning Briefing : Traders Await -2-	26/02
Pulmonx Shares Fall After Wells Fargo Downgrade	23/02
Earnings Flash (LUNG) PULMONX CORPORATION Reports Q4 Revenue $19.3M, vs. Street Est of $18.2M	21/02
Pulmonx Corporation Provides Earnings Guidance for the Full Year 2024	21/02
Pulmonx Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer	21/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pulmonx Corporation

Aandelen

LUNG

US7458481014

Andere talen

Filters